Research programme: Lassa virus inhibitors - RetroVirox
Latest Information Update: 28 Apr 2019
Price :
$50 *
At a glance
- Originator RetroVirox
- Class Antivirals; Small molecules
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lassa fever
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for research development in Lassa-fever in USA